MedImmune and Micromet have initiated a Phase I trial of MEDI-565 (MT111) in patients with advanced gastrointestinal cancers.

The dose-escalation study is designed to evaluate the safety, tolerability, and anti-tumour activity of the product candidate in adults with advanced gastrointestinal cancers.

Dose escalation in subsequent cohorts will be based on safety and tolerability.

After the maximum tolerated dose is established, additional study subjects with refractory colorectal or pancreatic cancer will be included in a dose-expansion phase to further assess the safety and anti-tumour activity.

MEDI-565 (MT111) is a BiTE antibody designed to direct a patient’s T cells, the body’s most potent killer cells, against cancer cells that express carcinoembryonic antigen.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.